Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

MBIO
Mustang Bio, Inc.
stock NASDAQ

At Close
Dec 12, 2025 3:59:30 PM EST
1.20USD-2.049%(-0.03)71,487
1.19Bid   1.20Ask   0.01Spread
Pre-market
Dec 12, 2025 8:59:30 AM EST
1.21USD-0.820%(-0.01)1,344
After-hours
Dec 12, 2025 4:12:30 PM EST
1.20USD+0.418%(+0.01)100
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
07:46AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data   Benzinga
07:14AM EST  FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder   Benzinga
Jan 24, 2022
05:33PM EST  Mustang Bio Provides Update On Its IND Application For MB-207   Benzinga
08:56AM EST  B. Riley Securities Maintains Buy on Mustang Bio, Lowers Price Target to $6   Benzinga
Jan 7, 2022
02:07PM EST  Mustang Bio Highlights MB-106 CD20-Targeted CAR T Data Selected For Presentations At Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Feb. 3, Feb. 5   Benzinga
02:05PM EST  Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for   GlobeNewswire Inc
Jan 5, 2022
08:30AM EST  Mustang Bio to Participate in Three January 2022 Virtual Investor   GlobeNewswire Inc
Dec 16, 2021
08:38AM EST  Mustang Bio Added To NASDAQ Biotechnology Index   Benzinga
Dec 13, 2021
09:03AM EST  Mustang Bio Highlights Updated Interim Phase 1/2 Data At ASH   Benzinga
09:00AM EST  95% overall response rate, 65% complete response rate and favorable safety profile in patientstreatedwithmodified cell manufacturing process   GlobeNewswire Inc
Dec 9, 2021
08:30AM EST  Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a   GlobeNewswire Inc
Nov 12, 2021
08:17AM EST  Mustang Bio Q3 EPS $(0.19) Up From $(0.23) YoY   Benzinga
08:05AM EST  Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.   GlobeNewswire Inc
Nov 10, 2021
08:18AM EST  Mustang Bio Announces Exclusive Worldwide License Agreement With Leiden University Medical Centre For Clinical-Stage Lentiviral Gene Therapy With Curative Potential For RAG1 Severe Combined Immunodeficiency   Benzinga
08:00AM EST  Agreement expands Mustangs pipeline of lentiviral gene therapies for SCID   GlobeNewswire Inc
Nov 1, 2021
08:34AM EDT  Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy For Treatment Of B-Cell Non-Hodgekin Lymphomas   Benzinga
08:30AM EDT  Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell   GlobeNewswire Inc
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Sep 30, 2021
08:47AM EDT  Mustang Bio To Participate In Chardan's Virtual 5th Annual Genetic Medicines Conference Oct. 5   Benzinga
08:30AM EDT  Mustang Bio to Participate in Chardans Virtual   GlobeNewswire Inc
Sep 28, 2021
08:30AM EDT  Mustang Bio Announces MB-101   GlobeNewswire Inc
Sep 9, 2021
08:30AM EDT  Mustang Bio to Participate in Three September 2021 Investor   GlobeNewswire Inc
Aug 16, 2021
04:07PM EDT  Mustang Bio Q2 EPS $(0.16) Up From $(0.32) YoY   Benzinga
04:01PM EDT  Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2021.   GlobeNewswire Inc
Aug 13, 2021
10:03AM EDT  Mustang Bio, Mayo Clinic Join Forces On New CAR T Tech In Tumor Settings   Benzinga
Aug 12, 2021
04:58PM EDT  Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology   Benzinga
Aug 2, 2021
10:31AM EDT  Mustang Bio's Gene Therapy For Genetic Immunodeficiency Receives European PRIME Tag   Benzinga
08:22AM EDT  Mustang Bio Receives European Medicines Agency PRIME Designation For MB-107 To Treat X-Linked Severe Combined Immunodeficiency In Newly Diagnosed Infants   Benzinga
08:18AM EDT  Mustang Bio Reports Received European Medicines Agency PRIME Designation For MB-107 To Treat X-Linked Severe Combined Immunodeficiency In Newly-Diagnosed Infants   Benzinga
08:00AM EDT  Mustang Bio Receives European Medicines Agency PRIME Designation   GlobeNewswire Inc
Jun 17, 2021
08:02AM EDT  Mustang Bio Awarded $300K Massachusetts Life Sciences Center Tax Incentive   Benzinga
08:00AM EDT  Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive   GlobeNewswire Inc
Jun 16, 2021
08:30AM EDT  Mustang Bio to Present at the Raymond James Human Health   GlobeNewswire Inc
Jun 11, 2021
08:05AM EDT  The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts   Benzinga
07:28AM EDT  Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial   Benzinga
06:31AM EDT  Mustang Bio Offers Interim Phase 1/2 Data For MB-106 CD20-Targeted CAR T In Patients With Relapsed, Refractory B-Cell Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia: 93% overall response rate and 67% complete response rate   Benzinga
06:30AM EDT  Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity   GlobeNewswire Inc
Jun 7, 2021
08:00AM EDT  Mustang Bio to Host Key Opinion Leader Webinar on MB-106   GlobeNewswire Inc
Jun 3, 2021
08:02AM EDT  Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics   Benzinga
May 18, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021   Benzinga
09:27AM EDT  BTIG Sees 260% Upside In Mustang Bio With PT of $11; Early-Stage MB-101 Starts Dosing Brain Tumor Patients   Benzinga
08:16AM EDT  Mustang Bio And City Of Hope Announce First Patient Dosed In Phase 1 Clinical Trial Of MB-101 (IL13R2-specific CAR T cells) To Treat Leptomeningeal Brain Tumors   Benzinga
08:00AM EDT  Mustang Bio and City of Hope Announce First Patient Dosed in Phase   GlobeNewswire Inc
07:47AM EDT  BTIG Initiates Coverage On Mustang Bio with Buy Rating, Announces Price Target of $11   Benzinga
May 17, 2021
04:42PM EDT  Hearing BTIG Initiates Buy On Mustang Bio And Announces An $11 Price Target   Benzinga
May 14, 2021
04:33PM EDT  Mustang Bio Q1 EPS $(0.19) Up From $(0.28) YoY   Benzinga
04:30PM EDT  Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2021.   GlobeNewswire Inc
May 12, 2021
12:46PM EDT  Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected For Presentation At European Hematology Association 2021 Virtual Congress   Benzinga
12:45PM EDT  Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for   GlobeNewswire Inc
11:55AM EDT  UPDATE: Mustang Bio Shares Up 4.6%; Cantor Fitzgerald Issues Note Titled 'MB-106 EHA Abstract Data Looks Promising with Higher ORR/CR Than ASH; + Effects for CLL Patent'   Benzinga
May 10, 2021
07:35AM EDT  Mustang Bio Announces FDA Acceptance Of IND Application For MB-106 CD20-Targeted CAR T Therapy   Benzinga
07:30AM EDT  The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is expected to begin enrolling patients in the third quarter of this year   GlobeNewswire Inc
Apr 21, 2021
08:00AM EDT  Mustang Bio to Participate in Chardans 5th   GlobeNewswire Inc
Mar 24, 2021
04:35PM EDT  Mustang Bio FY20 EPS $(1.14), Up From $(1.29) YoY; Cash Position $98.8M   Benzinga
04:30PM EDT  Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2020.   GlobeNewswire Inc
Mar 4, 2021
08:00AM EST  Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Mustangs management team will participate in three virtual investor conferences in March 2021.   GlobeNewswire Inc
Feb 26, 2021
08:00AM EST  Mustang Bio Joins Global Movement to Raise Awareness for Rare   GlobeNewswire Inc
Feb 2, 2021
07:42AM EST  Mustang Bio Announces FDA Removes Clinical Hold For Pivotal Phase 2 MB-107 Clinical Trial; Plans To Enroll First Patient In MB-107 Pivotal Trial In Q2 Of 2021   Benzinga
07:30AM EST  Mustang Bio Provides Updates on its Lentiviral Gene Therapies for   GlobeNewswire Inc
Jan 31, 2021
04:32PM EST  Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More   Benzinga
Jan 26, 2021
08:07AM EST  The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 5, 2021
08:30AM EST  Mustang Bio to Participate in Three January 2021 Virtual Investor   GlobeNewswire Inc
Dec 26, 2020
01:53PM EST  Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More   Benzinga
Dec 21, 2020
08:04AM EST  Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 to Treat Leptomeningeal Brain Tumors   Benzinga
08:00AM EST  Mustang Bio and City of Hope Announce Initiation of Phase 1   GlobeNewswire Inc
Dec 15, 2020
08:23AM EST  Mustang Bio Director Lindsay Rosenwald Purchased 100,000 Shares @ Avg Price of $2.66/Share Reported in Form 4 Filing   Benzinga
Dec 7, 2020
07:36AM EST  Mustang Bio Highlights Presentation Of Interim Phase 1/2 Data For MB-106 In Patients With Relapsed Or Refractory B-cell Non-Hodgkin Lymphoma At ASH Meeting   Benzinga
07:30AM EST  Data presented at the 62nd American Society of Hematology (ASH) Annual Meetingshow extremely favorable safety profile and clinical activity   GlobeNewswire Inc
Dec 1, 2020
08:14AM EST  Mustang Bio Reports Will Host Key Opinion Leader Call On MB-106 For Treatment Of Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma   Benzinga
08:00AM EST  Mustang Bio to Host Key Opinion Leader Call on MB-106 for the   GlobeNewswire Inc
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 24, 2020
08:04AM EST  Mustang Bio Announces Positive Opinion From European Medicines Agency On Orphan Drug Designation For Its Lentiviral Gene Therapy For Treatment Of X-linked Severe Combined Immunodeficiency   Benzinga
08:00AM EST  Mustang Bio Announces Positive Opinion from the European Medicines   GlobeNewswire Inc
Nov 23, 2020
08:03AM EST  Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency   Benzinga
08:00AM EST  Mustang Bio and Minaris Regenerative Medicine Sign Technology   GlobeNewswire Inc
Nov 6, 2020
04:21PM EST  Mustang Bio Q3 EPS $(0.23) Up From $(0.25) YoY   Benzinga
04:20PM EST  Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2020.   GlobeNewswire Inc
Nov 4, 2020
09:25AM EST  Mustang Bio Reports MB-106 Data Selected For Presentation At American Society Of Hematology Meeting Dec. 5-8   Benzinga
09:25AM EST  Mustang Bio Announces MB-106 Data Selected for Presentation at the   GlobeNewswire Inc
Oct 26, 2020
08:11AM EDT  Mustang Bio Announces Initial Phase 1 Data On MB-105 For Patients With PSCA-Positive Castration Resistant Prostate Cancer   Benzinga
08:01AM EDT  Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients   GlobeNewswire Inc
Oct 8, 2020
08:01AM EDT  Mustang Bio Announces MB-105 Data Selected For Presentation At The Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat   Benzinga
08:00AM EDT  Mustang Bio Announces MB-105 Data Selected for Presentation at the   GlobeNewswire Inc
Oct 7, 2020
04:15PM EDT  Horizon Technology Finance Provides Third Quarter 2020 Portfolio Update   PR Newswire
Oct 6, 2020
08:11AM EDT  Mustang Bio Licenses LentiBOOST Technology From SIRION Biotech   Benzinga
08:01AM EDT  Mustang Bio Licenses   GlobeNewswire Inc
Oct 2, 2020
05:54AM EDT  B. Riley FBR Initiates Coverage On Mustang Bio with Buy Rating, Announces Price Target of $9   Benzinga
Oct 1, 2020
08:30AM EDT  Mustang Bio to Participate in Chardans Virtual   GlobeNewswire Inc
08:06AM EDT  Mustang Bio Reports First Patient Dosed In Multicenter Phase 1/2 Trial Of MB-102   Benzinga
08:01AM EDT  Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2   GlobeNewswire Inc
Sep 22, 2020
08:09AM EDT  Mustang Bio Announces Orphan Drug Designation For MB-207 For Treatment Of X-Linked Severe Combined Immunodeficiency In Previously Transplanted Patients   Benzinga
08:01AM EDT  Mustang Bio Announces Orphan Drug Designation for MB-207 for the   GlobeNewswire Inc
Sep 10, 2020
08:00AM EDT  Mustang Bio to Participate in Three September 2020 Virtual   GlobeNewswire Inc
Sep 2, 2020
08:02AM EDT  Mustang Bio Announces Orphan Drug Designation For MB-107 For Treatment Of X-Linked Severe Combined Immunodeficiency In New Diagnosed Infants   Benzinga
08:00AM EDT  Mustang Bio Announces Orphan Drug Designation for MB-107 for the   GlobeNewswire Inc
Aug 31, 2020
08:11AM EDT  Mustang Bio Announces 'Rare' Pediatric Disease Designation For MB-207 For Treatment Of X-Linked Severe Combined Immunodeficiency In Previously Transplanted Patients   Benzinga
08:00AM EDT  Mustang Bio Announces Rare Pediatric Disease Designation for   GlobeNewswire Inc
Aug 17, 2020
08:24AM EDT  Mustang Bio Announces Rare Pediatric Disease Designation for its MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency   Benzinga
08:00AM EDT  Mustang Bio Announces Rare Pediatric Disease Designation for   GlobeNewswire Inc
08:00AM EDT  Mustang Bio to Present at the Virtual Fortress Biotech Corporate   GlobeNewswire Inc
Aug 12, 2020
07:30AM EDT  Fortress Biotech Announces Virtual Two-Day Corporate Access Summit   GlobeNewswire Inc
Aug 10, 2020
04:56PM EDT  Mustang Bio Q2 EPS $(0.32) Down From $(0.29) YoY   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC